2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. SHP2

SHP2

Src homology phosphatase 2; PTPN11

Src-homology-2-containing protein tyrosine phosphatase 2 (SHP2), encoded by the PTPN11 gene, is a 593 amino acid classical non-receptor protein tyrosine phosphatase (PTP). SHP2 is involved in diverse signalling pathways such as RAS-MAPK, PI3K-AKT, JAK-STAT and PD-1/PD-L1. Besides, SHP2 negatively regulates the activation of recombinant NLRP3 (NLR family, pyrin domain containing protein 3) inflammasome via mitochondrial homeostasis. SHP2 has been regarded as an extremely attractive target for human diseases therapies, particular in cancer.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-151464
    SHP2/HDAC-IN-1
    		Inhibitor
    SHP2/HDAC-IN-1 is a dual allosteric SHP2/HDAC inhibitor with IC50 values of 20.4 nM (SHP2) and 25.3 nM (HDAC1) respectively. SHP2/HDAC-IN-1 triggers efficient antitumor immunity by activating T cells, enhancing the antigen presentation function and promoting cytokine secretion. SHP2/HDAC-IN-1 can be used in the research of cancer immunoresearch.
    SHP2/HDAC-IN-1
  • HY-120159
    GS-493
    		Inhibitor
    GS-493 is a selective protein tyrosine phosphatase SHP2 (PTPN11) inhibitor with an IC50 of 71 nM. GS-493 is 29- and 45-fold more active toward SHP2 than related SHP1 and PTP1B. GS-493 blocks cellular motility and growth of cancer cells. Antitumor activity.
    GS-493
  • HY-173560
    SHP2 ATTEC degrader-1
    		Degrader
    SHP2 ATTEC degrader-1 is a SHP2 ATTEC degrader. SHP2 ATTEC degrader-1 has degradation rate of 83.31 at 1.0 μM for 24 h in the PANC-1 cell line. SHP2 ATTEC degrader-1 inhibits cell growth in vivo and in vitro. SHP2 ATTEC degrader-1 induces apoptosis and increases the expression of the epithelial marker ( E-cadherin)， and reduces the expression of interstitial markers (such as N-cadherin, Vimentin) (Pink: LC3 ligand (HY-174085); Black :linker HY-140468; Blue: SHP2 ligand (HY-174084).
    SHP2 ATTEC degrader-1
  • HY-171959
    SHP2-IN-39
    		Inhibitor
    SHP2-IN-39 (Example 63) is an inhibitor of SHP2 with an IC50 of 0.007 μM. SHP2-IN-39 can be used in the research of cancer.
    SHP2-IN-39
  • HY-155533
    YF704
    		Inhibitor
    YF704 (compound 4w) is a selective allosteric inhibitor of SHP2 (IC50=0.25 μM). YF704 shows antiproliferative activity and induces apoptosis in cancer cells. YF704 also downregulates Erk1/2 and Akt phosphorylation levels in cancer cells.
    YF704
  • HY-175204
    SHP2 protein degrader-3
    		Degrader
    SHP2 protein degrader-3 is a SHP2 AUTAC degrader. SHP2 protein degrader-3 shows dose-dependent SHP2 degradation ability (DC50 = 3.22 μM) and anti-tumor activity (IC50 = 5.59 μM) in HeLa cells. SHP2 protein degrader-3 induces degradation through the LC3-mediated autophagy pathway, which can be inhibited by lysosome inhibitors. SHP2 protein degrader-3 induces apoptosis in various cancer cells (HeLa cells, HepG2 cells, LoVo cells, Huh-7 cells) (SHP2 Ligand : (HY-100388); LC3 Ligand: (HY-10542); Linker : (HY-128834)).
    SHP2 protein degrader-3
  • HY-157318
    PB17-026-01
    		Inhibitor
    PB17-026-01 is a potent SHP2 allosteric inhibitor and shows the highest inhibitory activity with an IC50 value of 38.9?nM. PB17-026-01 can be used for the research of tumor.
    PB17-026-01
  • HY-168715
    SHP2-IN-33
    		Inhibitor
    SHP2-IN-33 (Compound D13) is an allosteric inhibitor of SHP2 with an IC50 of 1.2 μM. In cellular studies, SHP2-IN-33 demonstrates antiproliferative activity with an IC50 of 38 μM against Huh7 cells by arresting the G0/G1 cell cycle, promoting apoptosis (Apoptosis), and suppressing the MAPK signaling pathway. In an in vivo Huh7 xenograft mouse model, SHP2-IN-33 exhibits significant antitumor activity and favorable pharmacokinetics, including 54% oral bioavailability and a half-life of 10.57 hours. SHP2-IN-33 is a promising compound for studying tumor diseases associated with SHP2.
    SHP2-IN-33
  • HY-178983
    SHP2-IN-45
    		Inhibitor
    SHP2-IN-45 (Compound 6) is a potent, highly selective, and orally active SHP2 allosteric inhibitor. SHP2-IN-45 significantly reduces the expressions of IL-6, TNF-α, IL-1β, and iNOS. SHP2-IN-45 inhibits the polarization of M1-type macrophages. SHP2-IN-45 can inhibit the NF-κB pathway. SHP2-IN-45 can be used in the research of sepsis and acute lung injury.
    SHP2-IN-45
  • HY-149607
    SHP2-IN-22
    		Inhibitor
    SHP2-IN-22 is SHP2 allosteric inhibitor with an IC50 value of 17.7 nM. SHP2-IN-22 inhibits the proliferation, migration, and invasion of MIA PaCa-2 pancreatic cancer cells. SHP2-IN-22 can be used for Kirsten rat sarcoma viral oncogene (KRAS) mutant cancer research.
    SHP2-IN-22
  • HY-155276
    SHP2-IN-20
    SHP2-IN-20 (compound 193) is a SHP2 inhibitor with an IC50 value of 3 nM. SHP2-IN-20 can be used for glioblastoma research.
    SHP2-IN-20
  • HY-149759
    SHP2-IN-23
    		Inhibitor
    SHP2-IN-23 (compound 30) is an orally active SHP2 inhibitor (IC50=38 nM) with excellent in vivo efficacy and pharmacokinetic profiles. SHP2-IN-23 inhibits ERK phosphorylation with IC50=5 nM.
    SHP2-IN-23
  • HY-174239
    SHP2-IN-41
    		Inhibitor
    SHP2-IN-41 (Compound 4) is a SHP2 inhibitor with an IC50 of less than 0.1 μM. SHP2-IN-41 has an IC50 against KYSE-520 cells also less than 0.1 μM. SHP2-IN-41 can be used in the study of cancer.
    SHP2-IN-41
  • HY-175520
    SHP2-IN-42
    		Inhibitor
    SHP2-IN-42 is a src homology 2 domain-containing phosphatase 2 (SHP2) inhibitor with an IC50 of 15 nM. SHP2-IN-42 inhibits cell proliferation and induces apoptosis and G1 phase cell cycle arrest. SHP2-IN-42 can be used for the research of cancer, such as acute myeloid leukemia (AML).
    SHP2-IN-42
  • HY-157507
    JC-010a
    		Inhibitor
    JC-010a is a selective SHP2 allosteric inhibitor. JC-010a inhibits cancer cells proliferation. JC-010a can be used for the research of cancer.
    JC-010a
  • HY-121896
    DSHN
    		Activator
    DSHN is a potent small heterodimer partner (SHP) activator. DSHN inhibits Ccl2 expression and secretion by inhibiting p65 activation of Ccl2 promoter activity. DSHN can be used in research of cancer.
    DSHN
  • HY-153699
    SHP2-IN-14
    		Inhibitor
    SHP2-IN-14 (compound 27) is an orally active and potent SHP2 allosteric inhibitor (IC50=7 nM) with anti-tumor activity. SHP2-IN-14 inhibits tumor progression in NCI-H358 tumor bearing mice, exhibits good pharmacokinetic characteristics and safty.
    SHP2-IN-14
  • HY-162476
    SHP2-IN-28
    		Inhibitor
    SHP2-IN-28 (Compound 7188-0011) is an inhibitor of SHP2 (IC50=54.31 μM). SHP2-IN-28 exerts its inhibitory effect by binding to the variable site of SHP2 with high selectivity.
    SHP2-IN-28
  • HY-155272
    SHP2-IN-16
    		Inhibitor
    SHP2-IN-16 (compound 222) is a SHP2 inhibitor with an IC50 value of 1 nM. SHP2-IN-16 can be used for glioblastoma research.
    SHP2-IN-16
  • HY-144396
    SHP2-IN-8
    		Inhibitor
    SHP2-IN-8 is a highly potent, selective, and cellularly active allosteric SHP2 inhibitor with IC50 value of 23 nM and Ki of 22 nM. SHP2-IN-8 is reversible and noncompetitive. SHP2-IN-8 causes a significant thermal shift with the ΔTm of 7.01 °C. SHP2-IN-8 induces the apoptosis and inhibits the phosphorylation of AKT in Hela cells.
    SHP2-IN-8
Cat. No. Product Name / Synonyms Application Reactivity